Predictive factors of virological response to primary antiretroviral treatment;Facteurs prédictifs de la réponse virologique à un premier traitement antirétroviral

Presse Medicale

Volumn 33, Issue 5, 2004, Pages 310-315

  Faucher, Jean François ^a,h   Challier, B ^b   Chirouze, C ^a   Drobacheff, C ^a   Fischer, P ^c   Lang, J M ^c   Boyer, L ^d   May, T ^d   Froidure, M ^e   Chavanet, P ^e   Lescure, F X ^f   Strady, C ^g   Hoen, B ^a  

^a CISIH de Besançon 25   (France)

^b UNIVERSITY HOSPITAL OF BESANÇON   (France)

^c CISIH de Strasbourg (67)   (France)

^d CISIH de Nancy (54)   (France)

^e CISIH de Dijon (21)   (France)

^f CISIH d'Amiens (80)   (France)

^g CISIH de Reims (51)   (France)

^h HÔPITAL SAINT JACQUES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; AGED; ARTICLE; DISEASE COURSE; DRUG TOLERABILITY; FEMALE; FRANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; REBOUND; RETROSPECTIVE STUDY; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS LOAD;

EID: 12144288786     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0755-4982(04)98570-3     Document Type: Article

References (12)

1. Servais J, Schmit JC, Arendt V et al. Three-year effectiveness of highly active antiretroviral treatment in the Luxembourg HIV cohort. HIV Clin Trials 2000; 1: 17-24.
2. Moreno A, Perez-Elias MJ, Casado JL et al. Effectiveness and pitfalls of initial highly active antiretroviral therapy in HIV-infected patients in routine clinical practice. Antivir Ther 2000; 5: 243-8.
3. Paris D, Ledergerber B, Weber R et al. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort. AIDS Res Hum Retroviruses 1999; 15: 1631-8.
4. Paredes R, Moooft A, Kirk O et al. Predicton of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch Intern Med 2000; 160: 1123-32.
5. Girard PM, Guiguet M, Bollens D et al. Long-term outcome and treatment modifications in a prospective cohort of human immunodeficiency virus type 1-infected patients on triple-drug antiretroviral regimens. Triest Cohort Investigators. Clin Infect Dis 2000; 31: 987-94.
6. Meynard JL, Guiguet M, Rachline A et al. Facteurs prédictifs de réponse virologique à un traitement antirétroviral avec inhibiteur de protéase au cours de l'infection à VIH. Presse Med 2001; 30: 5-10.
7. Le Moing V, Chene G, Carrieri MP et al. Clinical, biologic and behavioral predictors of early immunologic and virologic response in HIV-infected patients initiating protease inhibitors. J Acquir Immune Defic Syndr 2001; 27: 372-6.
8. Easterbrook PJ, Newson R, Ives N, Pereira S, Moyle G, Gazzard BG. Comparison of virologic, immunologic, and clinical response to five different initial protease inhibitor-containing and nevirapine-containing regimens. J Acquir Immune Defic Syndr 2001; 27: 350-64.
9. Le Moing V, Chene G, Carrieri MP et al. Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS 2002; 16: 21-9.
10. Sous la direction du professeur JF Delfraissy. Traitement antirétroviral. Prise en charge des personnes infectées par le VIH- Rapport 2000. Médecine-Sciences Flammarion: 29-44.
11. Grabar S, Le Moing V, Goujard C et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 2000; 133: 401-10.
12. Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS 2001; 15: 1369-77.